Anti-TNF-alpha therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up


Creative Commons License

ÇAPKIN E. , KARKUCAK M. , Kiris A. , DURMUŞ İ. , KARAMAN K., Karaca A., ...More

RHEUMATOLOGY, vol.51, no.5, pp.910-914, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 5
  • Publication Date: 2012
  • Doi Number: 10.1093/rheumatology/ker434
  • Title of Journal : RHEUMATOLOGY
  • Page Numbers: pp.910-914
  • Keywords: ankylosing spondylitis, anti-TNF-alpha, pulse wave velocity, arterial stiffness, cardiovascular burden, NECROSIS FACTOR AGENTS, PULSE-WAVE VELOCITY, ANKYLOSING-SPONDYLITIS, ENDOTHELIAL FUNCTION, CARDIOVASCULAR EVENTS, RHEUMATOID-ARTHRITIS, DISEASE-ACTIVITY, INFLIXIMAB, ATHEROSCLEROSIS, INFLAMMATION

Abstract

Objective. The availability of new-generation drugs has provided significant success reflected by disease activity markers and clinical status in AS, but controversial reports necessitate further assessment of associated increased risk of cardiovascular burden that might persist. Hence this prospective clinical study evaluated the effectiveness of a 24-week anti-TNF-alpha therapy on vascular stiffness [pulse wave velocity (PWV)] in AS.